{"success":true,"data":{"pressRelease":{"id":"119536","rtpr_id":"nPn56ZtTja","ticker":"ARDX","exchange":"NASDAQ","all_tickers":["ARDX"],"title":"ARDX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ardelyx","author":"PR Newswire","published_at":"2026-08-14T14:07:00.433Z","article_body":"ARDX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ardelyx\n\nPR Newswire\n\nNEW YORK, Aug. 14, 2026\n\nArdelyx cut its 2026 IBSRELA revenue guidance by up to $80 million on August\n6, 2026, citing payer utilization-management restrictions -- and shares fell\nnearly 18% the next session.\n\nNEW YORK, Aug. 14, 2026 /PRNewswire/ -- Payer coverage restrictions allegedly\ncost Ardelyx (NASDAQ: ARDX) shareholders roughly 18% of their investment on\nAugust 7, 2026, when the stock closed at $4.00 after the Company attributed a\nfull-year IBSRELA guidance cut to increased step edits and more stringent\nprior authorizations. If you lost money on ARDX, click here to submit your\ninformation\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4752484-3&h=2251770605&u=https%3A%2F%2Fsuewallst.com%2Finvestigations%2Fardelyx-inc-investigation-ardx%3Fprid%3D200973%26wire%3D4&a=click+here+to+submit+your+information)\n. You may also contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com\n(mailto:jlevi@SueWallSt.com) or by telephone at (888) SueWallSt.\n\nAfter the close on August 6, 2026, Ardelyx lowered its full-year 2026 IBSRELA\nrevenue guidance to $350 million to $370 million from $410 million to $430\nmillion. On the Company's Q2 2026 earnings call, management claimed the extent\nof the payer restrictions \"was not something that one would anticipate.\" The\nsame reimbursement environment prompted the Company to withdraw its previously\nstated long-term $750 million XPHOZAH revenue target.\n\nThe reimbursement backdrop was not new to the Company. Ardelyx had previously\ndisclosed that XPHOZAH's loss of Medicare Part D coverage upon inclusion in\nthe ESRD PPS would result in a materially lower pace of revenue growth.\nSueWallSt notifies investors of a pending investigation into potential\nsecurities law violations relating to Ardelyx's disclosures concerning payer\ncoverage and utilization-management exposure.\n\nInvestors who purchased Ardelyx shares and suffered losses are encouraged to\nhave your ARDX losses reviewed at no cost\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4752484-3&h=1415840649&u=https%3A%2F%2Fsuewallst.com%2Finvestigations%2Fardelyx-inc-investigation-ardx%3Fprid%3D200973%26wire%3D4&a=have+your+ARDX+losses+reviewed+at+no+cost)\nor call (888) SueWallSt.\n\nWHY SUEWALLST : SueWallSt is powered by Levi & Korsinsky LLP. Levi &\nKorsinsky LLP has established itself as a nationally-recognized securities\nlitigation firm that has secured hundreds of millions of dollars for aggrieved\nshareholders and built a track record of winning high-stakes cases. The firm\nhas extensive expertise representing investors in complex securities\nlitigation and a team of over 70 employees to serve our clients. For seven\nyears in a row, Levi & Korsinsky has ranked in ISS Securities Class Action\nServices' Top 50 Report as one of the top securities litigation firms in the\nUnited States.\n\nFrequently Asked Questions About the ARDX Investigation\n\nQ: Who is conducting the ARDX investigation? A: Levi & Korsinsky, LLP is\ninvestigating potential securities fraud claims on behalf of investors who\npurchased ARDX securities. The firm is nationally recognized, ranked in the\nISS Top 50 for seven consecutive years, and has recovered hundreds of millions\nof dollars for aggrieved investors.\n\nQ: Who is eligible to participate in the ARDX investigation? A: Investors who\npurchased ARDX stock or securities and suffered financial losses may be\neligible. Eligibility is based on purchase date and documented losses -- not\non whether you still hold the shares.\n\nQ: How much did ARDX stock drop? A: Shares fell approximately 17.86% on August\n7, 2026, closing at $4.00, after Ardelyx cut its 2026 IBSRELA revenue guidance\nto $350-$370 million from $410-$430 million and withdrew its long-term $750\nmillion XPHOZAH target. Investors who purchased at allegedly inflated prices\nand suffered losses may be eligible to seek recovery.\n\nQ: What do ARDX investors need to do right now? A: Investors may gather\nbrokerage records showing purchase dates, share quantities, and prices paid.\nSubmit your information for a no-cost, no-obligation evaluation of your\npotential recovery\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4752484-3&h=2959612785&u=https%3A%2F%2Fsuewallst.com%2Finvestigations%2Fardelyx-inc-investigation-ardx%3Fprid%3D200973%26wire%3D4&a=Submit+your+information+for+a+no-cost%2C+no-obligation+evaluation+of+your+potential+recovery)\n. No immediate action is required to remain eligible to participate in the\ninvestigation.\n\nQ: What documents do I need to participate? A: Brokerage statements or trade\nconfirmations showing purchase dates, share quantities, prices paid, and any\nsubsequent sale dates and prices.\n\nQ: What if I already sold my ARDX shares -- can I still recover losses? A:\nYes. Eligibility is based on when you purchased, not whether you still hold\nthe shares. Investors who bought ARDX and sold at a loss may still participate\nin the investigation.\n\nQ: What does it cost me to participate? A: There is no upfront cost to submit\nyour information and review whether you may be eligible to recover. Should you\nchoose to participate in any resulting action, these matters are generally\nhandled on a contingency basis, with any attorneys' fees and expenses subject\nto court approval.\n\nQ: What if I live outside the United States? A: U.S. securities fraud\ninvestigations generally cover purchases on U.S. exchanges regardless of the\ninvestor's country of residence.\n\nCONTACT:\\\n\nLevi & Korsinsky, LLP\\\n\nJoseph E. Levi, Esq.\\\n\n33 Whitehall Street, 27th Floor\\\n\nNew York, NY 10004\\\n\njlevi@SueWallSt.com (mailto:jlevi@SueWallSt.com) \\\n\nTel: (888) SueWallSt\\\n\nFax: (212) 363-7171\n\nAttorney Advertising. Prior results do not guarantee similar outcomes.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/ardx-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-ardelyx-302851485.html\n(https://www.prnewswire.com/news-releases/ardx-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-ardelyx-302851485.html)\n\nSOURCE SueWallSt.com\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1812443/suewallst-logo-1-Logo.jpg?id=OA2886714\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn56ZtTja","title":"ARDX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ardelyx","author":"PR Newswire","ticker":"ARDX","created":"2026-08-14T14:07:00.433Z","tickers":["ARDX"],"exchange":"NASDAQ","article_body":"ARDX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ardelyx\n\nPR Newswire\n\nNEW YORK, Aug. 14, 2026\n\nArdelyx cut its 2026 IBSRELA revenue guidance by up to $80 million on August\n6, 2026, citing payer utilization-management restrictions -- and shares fell\nnearly 18% the next session.\n\nNEW YORK, Aug. 14, 2026 /PRNewswire/ -- Payer coverage restrictions allegedly\ncost Ardelyx (NASDAQ: ARDX) shareholders roughly 18% of their investment on\nAugust 7, 2026, when the stock closed at $4.00 after the Company attributed a\nfull-year IBSRELA guidance cut to increased step edits and more stringent\nprior authorizations. If you lost money on ARDX, click here to submit your\ninformation\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4752484-3&h=2251770605&u=https%3A%2F%2Fsuewallst.com%2Finvestigations%2Fardelyx-inc-investigation-ardx%3Fprid%3D200973%26wire%3D4&a=click+here+to+submit+your+information)\n. You may also contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com\n(mailto:jlevi@SueWallSt.com) or by telephone at (888) SueWallSt.\n\nAfter the close on August 6, 2026, Ardelyx lowered its full-year 2026 IBSRELA\nrevenue guidance to $350 million to $370 million from $410 million to $430\nmillion. On the Company's Q2 2026 earnings call, management claimed the extent\nof the payer restrictions \"was not something that one would anticipate.\" The\nsame reimbursement environment prompted the Company to withdraw its previously\nstated long-term $750 million XPHOZAH revenue target.\n\nThe reimbursement backdrop was not new to the Company. Ardelyx had previously\ndisclosed that XPHOZAH's loss of Medicare Part D coverage upon inclusion in\nthe ESRD PPS would result in a materially lower pace of revenue growth.\nSueWallSt notifies investors of a pending investigation into potential\nsecurities law violations relating to Ardelyx's disclosures concerning payer\ncoverage and utilization-management exposure.\n\nInvestors who purchased Ardelyx shares and suffered losses are encouraged to\nhave your ARDX losses reviewed at no cost\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4752484-3&h=1415840649&u=https%3A%2F%2Fsuewallst.com%2Finvestigations%2Fardelyx-inc-investigation-ardx%3Fprid%3D200973%26wire%3D4&a=have+your+ARDX+losses+reviewed+at+no+cost)\nor call (888) SueWallSt.\n\nWHY SUEWALLST : SueWallSt is powered by Levi & Korsinsky LLP. Levi &\nKorsinsky LLP has established itself as a nationally-recognized securities\nlitigation firm that has secured hundreds of millions of dollars for aggrieved\nshareholders and built a track record of winning high-stakes cases. The firm\nhas extensive expertise representing investors in complex securities\nlitigation and a team of over 70 employees to serve our clients. For seven\nyears in a row, Levi & Korsinsky has ranked in ISS Securities Class Action\nServices' Top 50 Report as one of the top securities litigation firms in the\nUnited States.\n\nFrequently Asked Questions About the ARDX Investigation\n\nQ: Who is conducting the ARDX investigation? A: Levi & Korsinsky, LLP is\ninvestigating potential securities fraud claims on behalf of investors who\npurchased ARDX securities. The firm is nationally recognized, ranked in the\nISS Top 50 for seven consecutive years, and has recovered hundreds of millions\nof dollars for aggrieved investors.\n\nQ: Who is eligible to participate in the ARDX investigation? A: Investors who\npurchased ARDX stock or securities and suffered financial losses may be\neligible. Eligibility is based on purchase date and documented losses -- not\non whether you still hold the shares.\n\nQ: How much did ARDX stock drop? A: Shares fell approximately 17.86% on August\n7, 2026, closing at $4.00, after Ardelyx cut its 2026 IBSRELA revenue guidance\nto $350-$370 million from $410-$430 million and withdrew its long-term $750\nmillion XPHOZAH target. Investors who purchased at allegedly inflated prices\nand suffered losses may be eligible to seek recovery.\n\nQ: What do ARDX investors need to do right now? A: Investors may gather\nbrokerage records showing purchase dates, share quantities, and prices paid.\nSubmit your information for a no-cost, no-obligation evaluation of your\npotential recovery\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4752484-3&h=2959612785&u=https%3A%2F%2Fsuewallst.com%2Finvestigations%2Fardelyx-inc-investigation-ardx%3Fprid%3D200973%26wire%3D4&a=Submit+your+information+for+a+no-cost%2C+no-obligation+evaluation+of+your+potential+recovery)\n. No immediate action is required to remain eligible to participate in the\ninvestigation.\n\nQ: What documents do I need to participate? A: Brokerage statements or trade\nconfirmations showing purchase dates, share quantities, prices paid, and any\nsubsequent sale dates and prices.\n\nQ: What if I already sold my ARDX shares -- can I still recover losses? A:\nYes. Eligibility is based on when you purchased, not whether you still hold\nthe shares. Investors who bought ARDX and sold at a loss may still participate\nin the investigation.\n\nQ: What does it cost me to participate? A: There is no upfront cost to submit\nyour information and review whether you may be eligible to recover. Should you\nchoose to participate in any resulting action, these matters are generally\nhandled on a contingency basis, with any attorneys' fees and expenses subject\nto court approval.\n\nQ: What if I live outside the United States? A: U.S. securities fraud\ninvestigations generally cover purchases on U.S. exchanges regardless of the\ninvestor's country of residence.\n\nCONTACT:\\\n\nLevi & Korsinsky, LLP\\\n\nJoseph E. Levi, Esq.\\\n\n33 Whitehall Street, 27th Floor\\\n\nNew York, NY 10004\\\n\njlevi@SueWallSt.com (mailto:jlevi@SueWallSt.com) \\\n\nTel: (888) SueWallSt\\\n\nFax: (212) 363-7171\n\nAttorney Advertising. Prior results do not guarantee similar outcomes.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/ardx-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-ardelyx-302851485.html\n(https://www.prnewswire.com/news-releases/ardx-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-ardelyx-302851485.html)\n\nSOURCE SueWallSt.com\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1812443/suewallst-logo-1-Logo.jpg?id=OA2886714\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-08-14T14:07:00.564243025Z","server_sent_at_ms":1786716420564},"received_at":"2026-08-14T14:07:00.631Z","source_url":"https://www.prnewswire.com/news-releases/ardx-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-ardelyx-302851485.html"},"analysis":{"id":"108522","press_release_id":"119536","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"SueWallSt, powered by Levi & Korsinsky LLP, notified investors of an investigation into potential securities law violations involving Ardelyx.\n\nThe investigation concerns the company's disclosures regarding payer coverage and utilization-management exposure following a recent guidance cut for IBSRELA.\n\nInvestors who purchased Ardelyx securities and suffered losses are encouraged to contact the firm for a no-cost review of their potential recovery.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{},"quotedText":"SueWallSt notifies investors of a pending investigation into potential securities law violations relating to Ardelyx's disclosures concerning payer coverage and utilization-management exposure.","namedEntities":{"people":[{"name":"Joseph E. Levi, Esq.","role":"Attorney"}],"products":["IBSRELA","XPHOZAH"],"companies":[{"name":"Ardelyx","ticker":"ARDX","relationship":"target"},{"name":"Levi & Korsinsky, LLP","relationship":"plaintiff law firm"},{"name":"SueWallSt","relationship":"plaintiff law firm"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by SueWallSt/Levi & Korsinsky. No new disclosure from the issuer; no certified class, no settlement. Routine investigation notice regarding prior guidance cut."},"tickerRelevance":{"others":[],"primary":"ARDX"},"globalImportance":15,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"SueWallSt, powered by Levi & Korsinsky LLP, notified investors of an investigation into potential securities law violations involving Ardelyx.\n\nThe investigation concerns the company's disclosures regarding payer coverage and utilization-management exposure following a recent guidance cut for IBSRELA.\n\nInvestors who purchased Ardelyx securities and suffered losses are encouraged to contact the firm for a no-cost review of their potential recovery.","key_figures":{},"named_entities":{"people":[{"name":"Joseph E. Levi, Esq.","role":"Attorney"}],"products":["IBSRELA","XPHOZAH"],"companies":[{"name":"Ardelyx","ticker":"ARDX","relationship":"target"},{"name":"Levi & Korsinsky, LLP","relationship":"plaintiff law firm"},{"name":"SueWallSt","relationship":"plaintiff law firm"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-14T15:22:28.328Z","global_importance":15,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":null,"modelName":"glm-4.7"}}